Summary
The provided FDA label excerpts for REZENOPY address emergency opioid overdose, intranasal dosing/administration, contraindications, and key warnings/precautions. The AI claims provided are exclusively about cost, insurance coverage, over-the-counter/state access, and program/manufacturer assistance, none of which are supported or contradicted by the supplied labeling excerpts. Therefore, there is substantial label-coverage mismatch with no on-label evaluable content.
Category Scores
Accurate Statements
Unsupported Statements
The cost of naloxone can vary depending on the formulation, dosage, and whether a prescription is required.
No information regarding pricing determinants or prescription requirement appears in the supplied FDA label excerpts for REZENOPY.
For individuals with prescription insurance, out-of-pocket costs for naloxone nasal spray can range from $0 to $118.
No out-of-pocket cost figures appear in the supplied FDA label excerpts.
Many prescription insurance plans cover naloxone nasal spray fully.
No insurance coverage or payer/benefit statements appear in the supplied FDA label excerpts.
For individuals without insurance, the price of naloxone prescription may range from $45 to $140.
No cash price ranges appear in the supplied FDA label excerpts.
The price of naloxone can differ by pharmacy and by the specific product, such as Narcan or Kloxxado.
No pharmacy-by-pharmacy or product-by-product pricing content appears in the supplied FDA label excerpts.
Naloxone can be obtained without insurance.
The supplied FDA label excerpts do not address availability with/without insurance.
Several state and local programs offer free naloxone.
The supplied FDA label excerpts do not discuss state/local program availability or free distribution.
Some pharmacies participate in discount programs for naloxone.
The supplied FDA label excerpts do not discuss pharmacy discount programs.
Some manufacturers provide co-pay assistance for people with commercial insurance.
The supplied FDA label excerpts do not discuss manufacturer co-pay assistance.
Naloxone is available over-the-counter in some areas.
The supplied FDA label excerpts do not discuss OTC status by location.
Naloxone is available at most pharmacies.
The supplied FDA label excerpts do not discuss pharmacy availability.
In some states, naloxone can be purchased without a prescription directly from a pharmacist.
The supplied FDA label excerpts do not address state laws or pharmacist dispensing without prescription.
Community health organizations and harm reduction centers often distribute naloxone at no cost.
The supplied FDA label excerpts do not discuss community organization or harm reduction distribution.
Naloxone is available in several forms, including nasal sprays and injectable solutions.
The supplied FDA label excerpts only describe REZENOPY as an intranasal nasal spray; they do not contain a cross-form availability statement for naloxone overall.
Nasal sprays, such as Narcan, are typically easier to administer in emergency situations.
The supplied FDA label excerpts do not compare ease of administration versus other formulations.
Injectable naloxone may be prescribed for home use or in clinical settings.
The supplied FDA label excerpts do not discuss injectable naloxone prescribing or home use.
Naloxone has been available for decades.
The supplied FDA label excerpts do not discuss market history/availability duration.
Patent expiry can be more relevant for brand-name medications where generic alternatives can emerge, potentially lowering costs.
The supplied FDA label excerpts do not discuss patents, generics, or cost drivers.
Specific naloxone formulations may have patents.
The supplied FDA label excerpts do not discuss patents for naloxone formulations.
DrugPatentWatch.com tracks patent information for pharmaceuticals and can indicate when market exclusivity for specific naloxone products might end.
The supplied FDA label excerpts do not discuss DrugPatentWatch.com or patent tracking.
When market exclusivity ends, generic competition could lead to price reductions for specific naloxone products.
The supplied FDA label excerpts do not discuss market exclusivity effects on pricing.
Numerous programs across the United States offer naloxone at no cost.
The supplied FDA label excerpts do not discuss national program availability.
These programs often include public health departments, syringe services programs, and non-profit organizations dedicated to overdose prevention.
The supplied FDA label excerpts do not describe program types or constituents.
Most insurance plans provide coverage for naloxone, including Medicare and Medicaid.
The supplied FDA label excerpts do not discuss payer coverage, including Medicare/Medicaid.
The specific co-pay amount for naloxone can vary by plan.
The supplied FDA label excerpts do not discuss copay structure or variation.
Contradictions
Important Omissions
Emergency opioid overdose indication and the REZENOPY-specific administration instructions (initial 1 spray; repeat every 2–3 minutes using a new nasal spray device; alternate nostrils; seek emergency medical assistance immediately; do not reuse; positioning/supine/safety instructions) are not addressed in the AI claims.
Importance:
High
REZENOPY contraindication (hypersensitivity to naloxone hydrochloride or excipients) and key warnings/precautions (risk of recurrent respiratory/CNS depression; limited efficacy with buprenorphine/pentazocine; precipitation of severe opioid withdrawal and monitoring) are not addressed in the AI claims.
Importance:
High
Safety Assessment
Potential Patient Risk:
Low
Although the AI claims are not evaluated as true/false against the supplied REZENOPY label (they are not label-supported), the claims are primarily about access/cost. However, they omit critical on-label emergency use instructions and warnings, which could indirectly affect proper use if relied upon instead of label guidance.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
AI-generated content focuses on cost/coverage/access and formulation comparisons, which are not present in the supplied FDA label excerpts; it also omits major REZENOPY dosing/administration instructions and warnings/precautions.
Suggested Improvement
Limit claims to information supported by the provided REZENOPY label excerpts (indication, intranasal dosing and repeat interval, emergency medical assistance requirement, contraindication, and key warnings/precautions). If cost/access is needed, cite label sections that address such topics; otherwise present it as non-label, externally sourced information.